Full Body Checkup in India: What’s Included, What It Costs and What Happens Next
Medically reviewed by Dr. Tarun Reddy, MBBS·Published 5 Aug 2026·Last reviewed 5 Aug 2026·~20 min read
A full body checkup is a bundle of blood and urine tests. Nothing gets scanned. Packages in India realistically run from about ₹1,000 to ₹5,000, and the expensive ones are mostly just bigger. But the thing that decides whether yours was money well spent is not printed on the report. It is whether anything actually changed in the three months after you read it.
Quick facts
Despite the name, nothing is scanned. A full body checkup is blood and urine, sometimes with an ECG.
Most Indian commercial packages are built around seven recurring panels: blood sugar, lipids, kidney, liver, thyroid, CBC and urine. That describes what the market sells. It is not a clinical screening schedule.
Test count is a marketing number. A 90-test package is not three times better than a 30-test one.
Randomised trials in more than 250,000 people found general health checks had little or no effect on death rates. The same body of evidence shows they do find disease, and do improve blood pressure and cholesterol control.
The gap between those two findings is treatment. In India, of adults with high blood pressure, 27.9% know it, 14.5% are on medication and 12.6% have it controlled.
Even among Indians already diagnosed with diabetes, only 7.7% meet all three targets for blood sugar, blood pressure and cholesterol.
Each marker has a reassessment window. HbA1c reads clearest at about 12 weeks, TSH at 6 to 8 weeks after a dose change, lipids at 4 to 12 weeks after starting treatment.
Fasting depends on which tests you booked. The word "checkup" tells you nothing about it. Routine lipid panels often do not require it; the fasting glucose bundled alongside them usually does.
The value of a checkup is not on the report — it is whether anything changes in the months after you read it.
A full body checkup is a pre-packaged set of laboratory tests, sold as a bundle because bundling is cheaper for the lab and cheaper for you than ordering each test one at a time at counter prices. You give one blood sample, usually fasting, plus a urine sample. Some packages add an ECG, a chest X-ray, or an ultrasound.
Most of us meet one the same way: the office books a camp, or a parent starts asking, or a friend's cousin in his thirties has a scare and suddenly everyone is getting tested. The name oversells it. Nothing looks inside you, no organ is imaged unless imaging is explicitly listed, and a normal report does not mean nothing is wrong. What a checkup does well is pick up the common conditions that stay silent for years before they announce themselves, and there is a short list of them: high blood sugar, high cholesterol, anaemia, an underactive thyroid, early kidney or liver strain. Catching those in the silent years is the one window where treatment changes the long arc of what happens to you.
What it does not do is detect most cancers, and it will not tell you whether your heart arteries are narrowing. Those need different tests, chosen for people at specific risk.
What tests are included in a full body checkup? Copy link
The seven panels are complete blood count, blood sugar (fasting glucose or HbA1c), lipid profile, kidney function, liver function, thyroid, and a urine routine. Most Indian commercial checkup packages, whatever the branding, are built around these same seven. This maps what the market sells. Which tests you personally need is a narrower question, and the section on risk below deals with it. The difference between a ₹1,000 package and a ₹5,000 one sits mostly at the edges.
Two samples, seven panels. One fasting blood draw produces six of them. The urine routine needs a separate sample, given at the same visit — which is why a blood-only package quietly drops one of the seven. Anything beyond these is an add-on, and whether it helps depends entirely on you.
The seven recurring panels, and what each looks for
Vitamin D and vitamin B12 are added to most mid-tier packages. They are useful when something justifies testing: symptoms, diet, malabsorption, medication, or another risk factor. Including them routinely in every asymptomatic adult is not universally recommended. A high rate of low readings among people who get tested does not by itself establish the case: those people were never a random sample. Vitamin D deficiency covers how to read that result, and why a low number does not automatically mean high-dose supplements.
Then there is everything else, and this is where the numbers on the banner come from. Tumour markers, extended hormone panels, allergy screens, arthritis profiles. These pad the test count handsomely, and a package advertising ninety tests has usually got there by adding exactly this kind of thing to the same seven panels everyone else runs. In a person with no symptoms and no specific risk, most of them create more questions than answers, and a few of them, tumour markers especially, are notorious for producing frightening numbers in perfectly healthy people.
Checkups can pick up common laboratory abnormalities. Whether finding them leaves you better off depends on what was tested, whether the result meant anything clinically, and what happened next. On their own, they do not make people live longer. The space between those two statements is what the rest of this article is about.
Start with the discouraging half. A Cochrane review pooled randomised trials that offered general health checks to adults who were not selected for any particular risk. It pooled 17 trials, with the outcome analyses covering more than 250,000 people. Health checks had little or no effect on death from any cause, and little or no effect on death from cancer, and the review graded both of those findings high-certainty, meaning further research is unlikely to overturn them. The effect on cardiovascular death was probably also little or none, graded moderate-certainty. Checkups did produce more new diagnoses. They did not produce longer lives.1
Now the encouraging half, which gets quoted far less often. A 2021 review in JAMA pulled together 19 randomised trials and 12 controlled observational studies and reached the same conclusion about mortality, and a different one about everything else. General health checks increased the detection of chronic disease. They produced moderate improvements in blood pressure and cholesterol control. They increased uptake of the cancer screening that does have randomised evidence behind it. They improved how people rated their own health.2
Two details from that review matter more than the headline. The first is timing: the benefits showed up while the programme was running and were generally not detectable more than five years after it stopped. A checkup is not a vaccine. Whatever it buys, it buys while the loop is live.
The second is the calendar. Fourteen of the 31 studies began before 1990, before statins were widely available, before most modern blood pressure drugs, before modern diabetes treatment. Those trials were, in effect, testing whether finding a problem helps when you cannot do much about it. The answer was no, and it is not obvious how far that answer travels to 2026.
India adds a third caveat. Those trials ran mostly in wealthy countries with functioning primary care, which means the comparison group was not going untested. They were already seeing a GP, already having their blood pressure taken. What the trials measured was the value of adding a systematic check on top of that. The ICMR-INDIAB study surveyed 113,043 adults across 31 states and projected that 101 million people have diabetes, 136 million have prediabetes, 315 million have hypertension, and 213 million have high cholesterol.3 A large share do not know it. If you have never been tested, you are not in the situation those trials studied.
So the real position sits between the two poles the marketing occupies. For adults aged 30 and over who have never been screened, blood pressure and diabetes screening is what India's own programme already recommends, and it is a reasonable place to start. After that first assessment, which tests you need and how often depends on what the results showed, what symptoms you have, what you are taking, whether you are planning a pregnancy and what your own risk factors are. There is no single interval that fits everybody.
What changes with age is how big the panel needs to be. If you are 28, well, and have nobody in the family with diabetes or heart disease, a ninety-test package every single year is more than the situation calls for. Every extra test on a healthy person is one more chance of a red flag that means nothing. Then comes the fortnight of quietly worrying about it. A smaller panel, taken seriously and actually discussed with someone, will do more for you than a longer one that gets filed. The variable that separates the two was never the number of tests. It is the phrase acted on properly.
A blood test is a measurement. Measurements do not treat anything. Between finding a problem and being better off there is a chain of steps: being told, understanding it, starting something, staying on it, checking it worked. Every step loses people.
India has good national data on exactly where they are lost. The National NCD Monitoring Survey looked at adults with high blood pressure and followed them along that chain. Of every 100 people who had hypertension, 27.9 were aware of it, 14.5 were taking medication for it, and 12.6 had it controlled below 140/90 mmHg.4
Most of the loss happens after the test. Of 100 Indian adults with high blood pressure, 28 know it, 15 are on treatment and 13 have it controlled. Finding it is the biggest single gap — and it is still less than half the journey.
And the reason those 72 people never find out is not mainly money, which is the assumption most of us start from. A 2025 meta-analysis pooling 40 Indian studies on health-seeking for non-communicable disease found the most commonly reported barrier was simply not thinking the problem was serious enough to act on — 47.9% of responses, against 32.6% citing financial constraints, though the estimate for cost varied so much between studies that the two overlap.5 Which is the whole difficulty with these conditions in one line. High blood pressure does not hurt. Nothing about a rising HbA1c feels like anything at all. Feeling fine is not evidence, and it is the most persuasive evidence most of us think we have.
Read that honestly and it cuts both ways. The single biggest loss is at the first step, and that step is testing. Seventy-two people in a hundred never find out. That is the strongest argument anyone can make for getting a first checkup in India, and it is a better argument than any of the ones on the booking pages.
But look at what happens to the twenty-eight who do find out. Fewer than half of them ever reach control. Diagnosis was necessary and it was nowhere near sufficient.
The same pattern shows up in diabetes, and more starkly, because there the researchers measured everything at once. Using the ICMR-INDIAB sample, investigators examined adults who already knew they had diabetes and asked how many were meeting the three targets that determine whether diabetes damages you: blood sugar, blood pressure and cholesterol. Individually, 36.3% had good glycaemic control, 48.8% had blood pressure control and 41.5% had LDL cholesterol control. All three together: 7.7%.6
Every one of those people had been tested. Most of them repeatedly. So what is the bottleneck, if not the test?
The problem is not only patients
As you would expect, the first assumption is that people are not taking their medicine. Some of it is that. A large part of it is the system on the other side of the counter, and there is a name for it: therapeutic inertia, the tendency for treatment to stay unchanged while a number sits out of range.
A retrospective cohort of 81,573 people with type 2 diabetes in UK general practice measured it directly, in a health system with universal access and free prescriptions. Among those already taking two oral diabetes drugs whose HbA1c had crossed 8%, the median time until anything was added to their treatment was more than 6.9 years. Across everyone on two drugs, average HbA1c had already reached 9.1% by the point anything changed.7
Nearly seven years of abnormal results, correctly measured, correctly reported, and filed. If that can happen inside an organised health system, it can certainly happen to a PDF that lands in your inbox at 6am with four values in red and no phone call attached.
This is the practical reason a checkup sold as a standalone product tends to underperform. The laboratory's job usually ends with producing and reporting an accurate result. Interpretation, communication and follow-up need a clearly identified clinician or care team, and where nobody has been named, that next step is the one most easily missed.
The counterweight to all of the above is that the treatments themselves work, and the size of the effect is well quantified. This is why the diagnosis still matters: not because the knowledge helps, but because of what the knowledge lets you start.
What each lever buys, from randomised evidence
What changes
By how much
What follows
Systolic blood pressure
−10 mmHg
About 20% fewer major cardiovascular events, 27% fewer strokes and 13% lower death from any cause, pooled across 123 trials and 613,815 people8
LDL cholesterol
−39 mg/dL
About 21% fewer major vascular events per 1 mmol/L lowered, across 27 trials and roughly 175,000 people, with no threshold below which the benefit stopped9
Prediabetes, treated with lifestyle change
28.5% RRR
In 531 Asian Indians with impaired glucose tolerance, three-year diabetes incidence fell from 55.0% to 39.3%. Six people needed to be treated to prevent one case10
Body weight, in early type 2 diabetes
−10 to 15 kg
Remission in 46% at one year versus 4% on usual care — and the rate tracked the weight, not the diagnosis: 7% for those who lost under 5 kg, 57% for 10 to 15 kg, 86% for 15 kg or more11
The last row is the one to sit with. In that trial, everyone was diagnosed. Everyone was told. What separated the person who ended the year off medication from the person who did not was the size of the change they made afterwards. Nobody went into remission by being tested.
Lifestyle measures matter in all four of those rows. Whether medication belongs alongside them depends on the result itself, your overall cardiovascular risk, what else you have been diagnosed with, and how large a change is needed. That is a clinical judgement, and it gets made in a consultation, which is the part of a good checkup that earns its money.
The report usually lands as a PDF on WhatsApp somewhere around six in the morning, with a few values in red and nobody attached to explain them. What happens next is what the evidence above is really about. It is unglamorous, and it is most of the value.
Patient safety research calls this closing the loop: a test is not finished when the result is produced, but when it has been interpreted, communicated and acted on, with the follow-up actually completed. Failure to close that loop is a recognised cause of diagnostic error, and that responsibility belongs to clinicians and health systems.12 What follows is not a protocol your doctor is working through, and it is not a checklist to hold them to. It is that principle rewritten from where you are standing, because you are the only person present at every step.
Confirm before you actA single abnormal value is a hypothesis, not a diagnosis. Blood sugar, liver enzymes and TSH all move for boring reasons: a bad night, a recent illness, a heavy meal you forgot counted. Many isolated borderline results are repeated or confirmed before any treatment starts, but the right next step varies: some markers need the same test repeated, some need a different confirmatory test, some justify treatment on overall risk without waiting, and some need assessment now. Which of those applies depends on the marker, how far outside the range it sits, whether you have symptoms and what your background risk is. That judgement is the doctor's, and it is the single most useful thing to bring to the appointment.
Ask what the number is attributable to, and decide the leverThis part is the doctor's work, and the question is worth asking out loud. The same raised SGPT means fatty liver alongside a high triglyceride and an expanding waist, and means last month's viral fever if it stands alone. A high HbA1c means something different if your haemoglobin is low. That pattern reading is what turns a result into a decision, and it is the reason a report emailed with no interpretation does so much less for you than the same report discussed for ten minutes. What comes out of it is a lever: lifestyle change, a prescription, or both. "Eat better and exercise" is not a lever; it is a mood. "Fifteen kilograms" is a lever, because the trial evidence attaches a number to it. So is "start treatment for blood pressure". Vague plans produce the 7.7% figure above.
Agree the target and the date with your doctor, and write both downThe target is the number you are aiming for: an LDL, a blood pressure, an HbA1c. It has to be set by the person treating you, because the right target depends on your age, your other conditions and what you are already taking. The date is when the two of you will look again. Ask for both before you leave, and put them somewhere you will find them. Treating towards an agreed number, and reviewing it on a set date, is a recognised clinical strategy in its own right. It has a name, treat-to-target; the principle originated in hypertension and diabetes and was later formalised across rheumatic disease.13 Which target, though, is not a detail. Lowering systolic blood pressure to below 120 rather than 140 reduces deaths, while pushing HbA1c below 6% in type 2 diabetes was found to increase them.14 That is the clearest possible argument for the target being set by the person treating you. Therapeutic inertia is what fills the vacuum when nobody has written down what should trigger a change.
Re-test on the biological clock, not the calendarA repeat test done too early measures the drug's arrival, not its effect. Done too late, it wastes months. Each marker has a clinically useful reassessment window, and your body sets where it falls.
When to test again, and why the interval is not arbitrary Copy link
Nobody sends you an SMS about this one. The lab will happily remind you about next year's package; it will not tell you that the test you actually need is due in eight weeks. This is the least-discussed part of the whole subject and the most practical. Once you start doing something about a result, the question stops being "how often should I get a full body checkup" and becomes "when will this particular number be able to tell me whether the thing I started is working".
Each marker has a reassessment window. Each needs a set amount of time before a repeat gives a clear read on whether a treatment is working. Testing before the window opens measures the drug arriving, not the drug working.
Four common examples, based on clinical guidelines and the evidence behind them:
Typical reassessment windows, after a treatment starts or changes
Marker
Re-test at
Why that long
Lipid profile
4 – 12 weeks
The response to a cholesterol-lowering drug is essentially complete within weeks. Guidelines put the first check at 4 to 12 weeks after starting or adjusting, then every 3 to 12 months once stable15
TSH
6 – 8 weeks
Thyroid hormone replacement takes roughly six weeks to reach steady state, so a TSH drawn at three weeks reflects a dose that has not finished arriving16
HbA1c
about 12 weeks
It reflects roughly the previous two to three months, weighted towards recent weeks — around half the movement towards a new level happens in the first 30 days.17 It therefore starts shifting earlier, but three months gives the clearest read on a sustained change. Quarterly when treatment has changed or you are not at target; twice a year once you are18
Blood pressure
days to weeks
The fastest of the four, which is why it is checked at visits rather than by appointment, and why home readings are more useful than an annual one
Notice what this does to the standard advice. For someone with normal results, no new symptoms and no change in treatment, the next screening interval should follow age, risk and the particular tests involved. For someone who has just started treatment for anything, an annual cycle is far too slow: it puts the first honest look at the result nine months after the moment it could have been read, which is precisely the gap where seven years of inertia gets built.
And for someone with a normal report who changes nothing, repeating the whole panel every six months because a package was on offer produces noise. Noise is not information. Let the interval follow whatever you are actually doing about the result.
This is a different product, and separating it clearly matters. When people search for a full body scan they usually mean whole-body MRI, CT or PET imaging sold as cancer screening. That is not what a checkup package contains, and the evidence for it is much weaker than the marketing suggests.
A systematic review pooled whole-body MRI findings across twelve studies and 5,373 people with no symptoms. Around a third, 32.1%, had a finding classed as critical or indeterminate, which is a startling number to sit with if you are the one on the table. Separated out, 13.4% were critical and 13.9% indeterminate. What became of those findings afterwards is mostly unrecorded: only 12.6% were ever verified at all. Where false positives were counted, in six of the twelve studies, they came to 16%, though the confidence interval on that estimate runs from 2% to 66%, which is a statistician's way of saying nobody really knows. The authors concluded that whole-body MRI should not be offered for preventive screening outside a research setting.19
Professional bodies take the same line. The practical problem is the cascade: a scan sensitive enough to catch something early is sensitive enough to catch a great deal that would never have troubled you, and each of those findings has to be chased with more imaging, sometimes a biopsy, and months of worry. CT adds radiation on top.
Whole-body MRI does have a real role in people carrying specific inherited cancer syndromes, where the baseline risk of finding something true is high enough to change the arithmetic entirely. For everyone else, the money buys more health if it goes on the boring tests and the follow-up instead.
Age is only a rough guide. Family history, symptoms and your own risk factors matter more. That makes this a conversation with a doctor, and it is one most booking pages are not equipped to have with you.
The table below separates three things commercial packages tend to blend into one list, because they carry very different weight. Column two is what India's own national programme actually offers, which is the only screening most Indians will be invited to without asking. Column three is screening that exists under other guidelines and is worth raising with a doctor, where the recommended age and method genuinely differ between bodies. Column four is risk-triggered: reasonable when something specific about you calls for it, and not a default.
India's population-based screening runs through primary care under the NP-NCD framework. It covers everyone aged 30 and above for hypertension, diabetes and oral cancer, and women aged 30 and above for cervical and breast cancer, with clinical breast examination and visual inspection using acetic acid as the first-line methods, where American and European schedules reach for mammography and cytology.20 That is a different starting point from the American or European schedules most package marketing borrows from, and it is the one that applies by default here.
A starting point for discussion — not a universal screening schedule
Age
India's population programme
Other screening to discuss
Risk-triggered tests
20s
Blood pressure measurement as part of routine care
Cervical screening, where the starting age and method depend on the guideline followed
Blood sugar, thyroid, ferritin or lipids based on BMI, symptoms, pregnancy plans and family history
30s
Hypertension, diabetes and oral cancer from age 30. Cervical and clinical breast screening for women from 30
Lipid assessment based on cardiovascular risk
CBC, ferritin, thyroid, liver or kidney testing when something indicates it
40s
Continue the same NCD and cancer screening
Mammography, weighing the guideline, family history and what is actually accessible to you
ECG or further cardiac testing only where there is a clinical reason
50s and beyond
Continue NCD screening and age-appropriate cancer screening
Colorectal, breast, cervical and prostate decisions according to the applicable guideline
Bone density and others according to age and risk
Screening recommendations differ between India's public programme and international professional-body guidelines, on starting age, on interval and sometimes on the test itself. Treat this table as a starting point for a conversation, not a schedule to work through.
What changes for men and women
Commercial packages generally run the same core laboratory panels for men and women. What differs is the risk-based testing and the cancer screening layered on top.
Screening ages and methods differ between India's public programme and international guidelines, sometimes considerably. Cervical, breast, colorectal, prostate and bone-density screening are therefore best discussed against the guideline being followed, your own risk, and what is available where you live.
For women, cervical and breast screening are the two that run on their own schedule, separate from any package, and India's programme starts both at 30. Bone density becomes a question after menopause. Thyroid testing and ferritin come up more often in women, and where periods are heavy, iron deficiency is a common enough explanation for fatigue to be checked.
For men, PSA is the test that generates the most argument, and guidelines disagree on who should have it and when. It belongs in a conversation with a doctor, because a raised PSA has several harmless causes and the follow-up is invasive enough to want a clear reason for starting.
Packages sold as "women's" or "men's" bundle some of this and skip the rest. Read the inclusion list before assuming the label has done the thinking for you.
What a "heart checkup" actually contains
Heart packages are sold separately and repay a little understanding, because the useful parts are cheap and the expensive parts are often the least informative. For someone without symptoms, the tests that carry real predictive weight are a lipid profile, blood pressure measured properly on more than one occasion, blood sugar, and a record of whether you smoke — which is to say, most of a standard checkup plus a cuff. An ECG is not recommended purely because you have reached a particular age: the US Preventive Services Task Force recommends against resting or exercise ECG screening in asymptomatic adults at low cardiovascular risk, and found the evidence insufficient at intermediate or high risk.21 It becomes appropriate when symptoms, examination findings, your calculated cardiovascular risk or a planned treatment give a clinical reason for it. A treadmill test in a person with no symptoms produces a meaningful number of false positives and is not a general screening tool. Symptoms change all of this. New chest discomfort, breathlessness that is severe or came on suddenly, fainting, or symptoms that are getting worse quickly need prompt medical assessment, and some of those presentations need emergency care rather than an appointment.
Cancer screening is the part packages handle worst. Cervical, breast and colorectal screening have randomised evidence behind them and specific age windows. A tumour marker thrown into a wellness bundle does not substitute for any of them, and was never designed to.
What should a full body checkup cost in India? Copy link
As of August 2026, commonly advertised packages start at roughly ₹1,000, while broader panels and hospital packages run to ₹5,000 and beyond. Prices vary considerably by city, by provider, by which tests are actually included and by whatever discount is running that week.
You will also see much lower numbers on booking sites: ₹399, ₹499. These are typically introductory, coupon-linked or city-specific offers. Before booking, confirm two things: the final amount payable, and which laboratory will actually process your sample.
How we checked prices. These figures come from publicly listed packages at national diagnostic chains and aggregator platforms, reviewed in August 2026. They are market examples rather than endorsements or quotes, and package pricing in India moves quickly enough that anything specific dates fast. Check the provider's own page for the current number.
If you are on a lab's mailing list you already know the rhythm of this: the discount SMS in the first week of the month, the same package at a different price each time. Check three things before you pay. Whether the lab is NABL accredited, since accreditation is the closest thing to a quality floor. Whether the price you are seeing is the offer price or the MRP, because a package listed at "₹8,000, now ₹1,899" is usually just the price. And what the package actually contains, because a 90-test count is often built by counting each line of the CBC separately.
Hospital packages generally cost more than standalone labs, and much of that gap is the consultation, the physical examination, any imaging, and the overhead of the facility — along with the fact that an abnormal result has somewhere to go. Given everything above, that is not a bad thing to be paying for. Quality itself is a separate question from price, and the things to look at are accreditation, internal quality-control systems, how samples are handled, and which laboratory runs the assay.
Two labels to decode, neither of which is a standardised product. Providers generally use master health checkup for a mid-tier package, often the recurring panels plus an ECG, a chest X-ray and a physician consultation, and executive health checkup for something broader, frequently employer-funded, adding imaging such as an ultrasound or a treadmill test. Neither term carries a fixed test list, so two providers using the same word may be selling quite different things. The consultation is the part that earns its money in both. The extra imaging is where the price climbs and the evidence thins.
On money back: preventive health checkups attract a deduction under Section 80D of the Income Tax Act, within the overall 80D limit, and it applies under the old tax regime, so whether it is available to you depends on which regime you have opted for. Ask whoever files your return. Health insurance policies increasingly bundle an annual checkup as a no-claim benefit, so check before you pay out of pocket. Neither is a reason to book.
How to prepare, and does fasting matter? Copy link
Fast when the tests you have booked call for it, and follow the lab's own instructions, because they are specific to the panel you ordered. A fasting plasma glucose genuinely requires it. A routine lipid profile mostly does not: the European Atherosclerosis Society and the EFLM recommend non-fasting samples for routine lipid testing, with fasting reserved for particular situations such as very high triglycerides.22 Most Indian packages bundle fasting glucose alongside the lipids, so the visit ends up being a fasting one regardless. The glucose is what requires it.
Where fasting applies, make it 8 to 12 hours and count from your last calorie, because the chai counts. Water is fine and you should drink it, because a dehydrated arm makes the draw harder and can nudge some values. Most labs advise skipping alcohol for 24 hours beforehand, since a recent drink can lift liver enzymes and triglycerides in ways that say nothing about your baseline.
Go in the morning if you can. TSH follows a daily rhythm, peaking late at night and reaching its lowest point in the afternoon, so an afternoon sample can read meaningfully lower than a morning one in the same person.23 Keep taking your regular medication unless your doctor has said otherwise. If you take levothyroxine, give the sample before that morning's dose, since free T4 peaks a few hours after you swallow it, so a post-dose sample reads that peak instead of your steady state.23
Stop high-dose biotin beforehand. Biotin is a well-established cause of interference in several commonly used thyroid immunoassays, which build biotin into their own chemistry. It can push T3 and T4 falsely high and TSH falsely low, and has led to people being wrongly diagnosed with hyperthyroidism. The American Thyroid Association advises stopping for at least two days; later work suggests three to five is safer at high doses.24
Routine blood collection generally does not need postponing simply because you are menstruating. Urine testing is the part that can be affected, since contamination may produce blood or protein that has nothing to do with your kidneys or bladder. Tell the laboratory, or reschedule that component when it is practical to do so.
Home collection is a good option, and most labs now include it free above a certain package value. The sample is usually analysed on the same equipment as one drawn at a centre. That is not quite the same as saying the result is identical. Collection technique, tube filling, storage temperature, transport time and processing speed all affect quality, and a home draw adds distance to every one of those. Reputable labs manage it well. What you are really buying is the removal of the excuse. A great many checkups die at the stage of nobody wanting to drive somewhere at seven in the morning without breakfast. Two practical things to confirm. First, which accredited laboratory will process the sample, who is responsible for collecting and transporting it, and whether the provider follows documented sample-handling procedures — accreditation covers a laboratory's systems and scope, so it does not attach to an individual collector, and subcontracted collection is not automatically worse. Second, that the urine container is handed over at the same visit, since that is the part people routinely forget.
Most reports come back with a handful of values flagged in red, and most of those flags are not emergencies. Reference ranges are built so that a small percentage of perfectly healthy people fall outside them by definition, which means the more boxes a package ticks, the more red ink you should expect on a report that is telling you nothing is wrong. Run enough tests on a well person and something will be flagged.
Read the flagged values against each other first, and against the reference range second. The pattern carries more information than any single line. Then take the whole thing to someone who can tell you which of the four steps above applies.
None of which is a substitute for showing it to a doctor. Reading up on your own values is a good way to arrive at the appointment with better questions, and a bad way to replace it. The interpretation depends on your history, your medicines and an examination, and no article can supply those. If you take one thing from this page, let it be that the report is the beginning of the consultation.
Seek clinical review when an abnormality is substantial, unexpected, persistent, accompanied by symptoms, or sitting alongside other abnormal results that point the same way. Minor isolated deviations usually need context before anything else, and a report with one marginal red value is more often a reference-range artefact than a finding. Go sooner, without waiting for a routine checkup, if you have symptoms: unexplained weight loss, blood anywhere it should not be, a lump, persistent fever, breathlessness on exertion that is new, or chest discomfort. Symptoms need a diagnostic workup aimed at the symptom. A screening package is the wrong tool for that job and can be falsely reassuring.
Ask for personalised screening advice if you have a first-degree relative with premature heart disease, diabetes or a relevant inherited condition, if you are 30 or older and have never been screened, or if you are planning a pregnancy.
Seven core panels in almost every package: blood sugar, lipid profile, complete blood count, kidney function, liver function, thyroid, and a urine routine. Mid-tier packages usually add vitamin D and B12. Everything beyond that is an add-on whose value depends on your age, symptoms and family history.
How much does a full body checkup cost in India?
As of August 2026, commonly advertised packages start at roughly ₹1,000, with broader panels and hospital packages running to ₹5,000 and beyond. Prices vary by city, provider, included tests and whatever discount is live that week. Much lower advertised prices, ₹399 or ₹499, are typically introductory, coupon-linked or city-specific offers, so confirm the final amount payable and which laboratory will process your sample. Check too whether the lab is NABL accredited and whether home collection is included or billed separately.
Do I need to fast for a full body checkup?
Fasting is required when the tests you have booked, or the laboratory's instructions, specify it. Fasting plasma glucose is the clearest example. Many routine lipid profiles can be done without fasting, though fasting may still be requested for high triglycerides or a particular clinical question. Most Indian packages include fasting glucose, so in practice the visit is usually a fasting one. Where it applies, fast 8 to 12 hours, drink water, and avoid alcohol for 24 hours beforehand since it raises liver enzymes and triglycerides on its own. Morning appointments are better because several values, TSH especially, shift across the day.
Are full body checkups worth it?
They are worth it if you act on the result, and close to worthless if you do not. Randomised trials in over 250,000 adults found general health checks had little or no effect on death rates, though the same evidence shows they do detect disease and do improve blood pressure and cholesterol control. In India the case for a first test is strong, because an estimated 101 million adults have diabetes and a large share are unaware. The case for an annual 90-test package with no follow-up is weak.
What should I do after I get my report?
Four things, in order. First, decide with a doctor whether an isolated borderline value needs repeating, confirming with a different test, or acting on straight away; that depends on how large the abnormality is, whether you have symptoms, what the related results show and what your overall risk is. Second, ask what the number is attributable to, read alongside the others, and settle on the lever: lifestyle, a prescription, or both. Third, agree a target number and a review date, and write both down. Fourth, book the repeat test for the date that number can answer. Almost all of the health benefit of a checkup lives in those four steps.
How soon can I repeat a blood test to see if treatment is working?
It depends on the marker. Lipids can be rechecked 4 to 12 weeks after starting or adjusting a cholesterol-lowering drug. TSH needs 6 to 8 weeks after a levothyroxine dose change, because the hormone takes about six weeks to reach steady state. HbA1c reflects roughly the previous two to three months, weighted towards the most recent weeks, so it does begin moving earlier. About 12 weeks gives the clearest assessment of a sustained change. Testing well before these windows tells you much less than the number appears to promise.
How often should I get a full body checkup?
There is no universal interval for a "full body checkup". India's population programme offers screening for hypertension, diabetes and certain cancers from age 30, but what you need after that depends on the initial results, your symptoms, the medicines you take, pregnancy plans and your own risk factors. If you are on treatment for something, the relevant marker needs rechecking on its own clinical schedule, often within one to three months, and that is a different thing from booking another complete package.
Can I get a full body checkup done at home?
Many providers offer home collection, sometimes free above a minimum booking amount. The sample is generally analysed on the same equipment used for samples drawn at a centre, though it is not automatically identical: collection technique, tube filling, storage, transport time and processing delay all influence quality, and a home visit lengthens that chain. Confirm which accredited laboratory will process the sample, who is responsible for collection and transport, whether there is a separate collection charge, and roughly how quickly the sample reaches the lab. Hand over the urine container at the same visit, since that is the step people most often forget.
Is a full body checkup the same as a full body scan?
No. A checkup is blood and urine tests. A full body scan means whole-body MRI, CT or PET imaging, which is sold separately and is not recommended for people without symptoms. A systematic review found about a third of asymptomatic people scanned had critical or indeterminate findings, with roughly 16% false positives.
What is the difference between a master health checkup and an executive one?
Neither term has a standardised test list. Providers commonly use "master" for a mid-tier hospital package, often the recurring panels plus an ECG, a chest X-ray and a doctor consultation. "Executive" often refers to something broader, frequently employer-funded, adding imaging such as ultrasound or a treadmill test. The consultation is the valuable part of both; the added imaging is where cost rises fastest and evidence is thinnest.
Can a full body checkup detect cancer?
Mostly no. Standard packages are built to find common metabolic and organ problems. The cancer screening with randomised evidence behind it, cervical, breast and colorectal, runs on its own schedule and method. Tumour markers in a wellness bundle are not a substitute and frequently produce alarming results in healthy people.
Does a normal report mean I am healthy?
It means the tests you had were normal. Blood pressure, weight, smoking, sleep, mental health and cancer screening are not in a standard panel, and a normal report says nothing about any of them.
Krogsbøll LT, Jørgensen KJ, Gøtzsche PC. General health checks in adults for reducing morbidity and mortality from disease. Cochrane Database of Systematic Reviews. 2019;1:CD009009 — systematic review of randomised trials comparing general health checks with no health checks in adults unselected for disease or risk factors; 17 trials included, 15 reporting outcomes across more than 250,000 participants. Little or no effect on all-cause and cancer mortality (high-certainty evidence), probably little or no effect on cardiovascular mortality (moderate-certainty). Health checks increased new diagnoses. Trials ran largely in high-income settings with established primary care, so the comparison group was not untested — a material limitation when applying the finding to populations with low baseline screening. PMID 30699470
Liss DT, Uchida T, Wilkes CL, Radakrishnan A, Linder JA. General health checks in adult primary care: a review. JAMA. 2021;325(22):2294–2306 — narrative review of 19 randomised trials and 12 controlled observational studies. No consistent effect on mortality or cardiovascular events; associated with increased chronic disease detection and treatment, moderate improvements in blood pressure and cholesterol control, higher preventive service uptake and improved patient-reported outcomes. Benefits were generally observed during the active intervention period and not beyond about five years after it ended. Not a meta-analysis, so no pooled effect sizes; 14 of 31 included studies began before 1990, predating widespread statin and modern antihypertensive use.
Anjana RM, Unnikrishnan R, Deepa M, et al.; ICMR-INDIAB Collaborative Study Group. Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17). The Lancet Diabetes & Endocrinology. 2023;11(7):474–489 — population-based survey of 113,043 adults aged 20 and over across 31 states and union territories, surveyed 2008–2020. Projected 2021 national figures: 101 million with diabetes, 136 million with prediabetes, 315 million with hypertension, 213 million with hypercholesterolaemia. Cross-sectional; projections are modelled from the surveyed sample rather than directly counted, and fieldwork spanned twelve years. PMID 37301218
Amarchand R, Kulothungan V, Krishnan A, Mathur P. Hypertension treatment cascade in India: results from National Noncommunicable Disease Monitoring Survey. Journal of Human Hypertension. 2022 — nationally representative survey of adults aged 18–69 conducted 2017–18. Among those with hypertension, 27.9% (95% CI 25.5–30.3) were aware, 14.5% (12.7–16.5) were on treatment and 12.6% (11.0–14.3) were controlled. Blood pressure was measured at a single survey visit rather than confirmed on separate days, which tends to overestimate prevalence and therefore understate the proportion aware. doi:10.1038/s41371-022-00692-y
Haridoss M, Nandi D, Rajesh Lenin R, John SP, Anantharaman VV, Janardhanan R. Health-seeking behavior and its determinants for non-communicable diseases in India: a systematic review and meta-analysis. Frontiers in Public Health. 2025;13:1580824 — 64 studies included, 40 pooled. The most frequently reported barrier to seeking treatment was the illness not being considered serious, at 0.4785 (95% CI 0.4556–0.5013), ahead of financial constraints at 0.3263 (95% CI 0.1457–0.5069). The confidence intervals overlap, so the ordering of the two should not be over-read; heterogeneity was very high across the included studies, which differ in population, region and how barriers were asked about. PMID 40567983
Anjana RM, Unnikrishnan R, Deepa M, et al.; ICMR-INDIAB Collaborators. Achievement of guideline recommended diabetes treatment targets and health habits in people with self-reported diabetes in India (ICMR-INDIAB-13): a national cross-sectional study. The Lancet Diabetes & Endocrinology. 2022;10(6):430–441 — 5,789 adults with self-reported diabetes drawn from the ICMR-INDIAB sample. Good glycaemic control in 36.3%, blood pressure control in 48.8%, LDL control in 41.5%; only 7.7% (419 of 5,297) met all three targets. Diabetes status was self-reported, so the sample is people who already knew their diagnosis; the undiagnosed, whose control is likely worse, are not represented. PMID 35461575
Khunti K, Wolden ML, Thorsted BL, Andersen M, Davies MJ. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care. 2013;36(11):3411–3417 — 81,573 people with type 2 diabetes in the UK Clinical Practice Research Datalink. Median time from crossing an HbA1c threshold to intensification with an additional oral drug was 2.9, 1.9 and 1.6 years at 7.0%, 7.5% and 8.0% for people on one oral agent, and more than 7.2, 7.2 and 6.9 years respectively for those already on two. Mean HbA1c at the point of intensification was 8.7%, 9.1% and 9.7% for people on one, two and three oral agents respectively. Retrospective and UK-based; intensification may be under-captured where it happened outside primary care records, and clinically appropriate reasons for not intensifying cannot be distinguished from inertia. doi:10.2337/dc13-0331
Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. The Lancet. 2016;387(10022):957–967 — 123 studies, 613,815 participants. Every 10 mmHg reduction in systolic blood pressure was associated with a 20% lower risk of major cardiovascular events (RR 0.80, 95% CI 0.77–0.83), 17% for coronary heart disease, 27% for stroke, 28% for heart failure and 13% for all-cause mortality; the effect on renal failure was not significant. Tabular rather than individual-participant meta-analysis, and trial populations were generally higher-risk than the average person having a checkup. doi:10.1016/S0140-6736(15)01225-8
Cholesterol Treatment Trialists' (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. The Lancet. 2012;380(9841):581–590 — individual participant data from approximately 175,000 people. Statins reduced major vascular events by 21% per 1.0 mmol/L (about 39 mg/dL) LDL reduction (RR 0.79, 95% CI 0.77–0.81), with significant reductions in each risk stratum including those at under 10% five-year risk. Effects are proportional, so absolute benefit in a low-risk individual is small; the collaboration receives data from industry-funded trials, and harms were assessed less granularly than benefits.
Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V; Indian Diabetes Prevention Programme. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. 2006;49(2):289–297 — 531 Asian Indians with impaired glucose tolerance, median follow-up 30 months. Three-year cumulative diabetes incidence 55.0% in controls versus 39.3% with lifestyle modification; relative risk reduction 28.5% (95% CI 20.5–37.3), number needed to treat 6.4. Combining lifestyle change with metformin added nothing. Predominantly male sample (421 of 531) recruited in Chennai, so generalisability to women and to other regions of India is limited. PMID 16391903
Lean MEJ, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. The Lancet. 2018;391(10120):541–551 — 306 adults across 49 UK primary care practices. Remission at 12 months in 46% of the intervention group versus 4% of controls (OR 19.7, 95% CI 7.8–49.8), with remission strongly graded by weight lost: 7% at 0–5 kg, 34% at 5–10 kg, 57% at 10–15 kg and 86% at 15 kg or more. Open-label; restricted to people diagnosed within six years, with BMI 27–45 and not on insulin, so it does not describe long-standing diabetes. Remission fell to 36% at two years. PMID 29221645
Dahm MR, Georgiou A, Westbrook JI, et al. Closing the loop on test results to reduce communication failures: a rapid review of evidence, practice and patient perspectives. BMC Health Services Research. 2020;20:1052; and The Joint Commission. Quick Safety 52: Advancing safety with closed-loop communication of test results. 2019 — a test result is not complete until it has been interpreted, communicated and acted on, with follow-up closed. Failure to close that loop is a recognised contributor to diagnostic error, with reported rates of missed follow-up varying widely by test type and setting. The literature places this duty on clinicians, health systems and health IT, not on patients; the section above adapts the principle to what a patient can see and ask, which is an editorial reframing rather than a clinical recommendation. doi:10.1186/s12913-020-05737-x
Zhao SS, Pittam B, Harrison NL, et al. Efficacy and safety of treat-to-target strategy studies in rheumatic diseases: a systematic review and meta-analysis. Seminars in Arthritis and Rheumatism. 2024 — treat-to-target means setting an explicit numerical goal, reviewing at defined intervals and escalating treatment until the goal is met. The principle originated in hypertension and diabetes, where it has been shown to improve outcomes, and was subsequently applied across rheumatic disease; in rheumatoid arthritis, 20 of 24 trials comparing it with usual care showed better clinical outcomes. Most of this trial evidence comes from established disease under specialist care rather than from screening-detected abnormalities in asymptomatic people, so it supports the principle rather than any specific target for a healthy adult after a checkup.
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Group; Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. New England Journal of Medicine. 2008;358(24):2545–2559; and SPRINT Research Group; Wright JT, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. NEJM. 2015;373(22):2103–2116 — ACCORD randomised 10,251 adults with type 2 diabetes at high cardiovascular risk to an HbA1c target below 6.0% or 7.0–7.9%; the intensive arm was stopped early for increased cardiovascular death (HR 1.35, 95% CI 1.04–1.76) and all-cause mortality (HR 1.22, 1.01–1.46). SPRINT randomised 9,361 adults at high cardiovascular risk without diabetes to a systolic target below 120 or 140 mmHg and found fewer cardiovascular events and lower all-cause mortality with the lower target, at the cost of more hypotension, syncope and acute kidney injury. Both are trials of a particular target in a selected high-risk population, so neither settles what target suits any individual, and neither describes screening-detected abnormalities in asymptomatic people. Read together they show the direction of benefit is target-specific and condition-specific.
Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. Circulation. 2019;139(25):e1082–e1143 — recommends assessing response with a fasting lipid panel 4 to 12 weeks after statin initiation or dose adjustment, then every 3 to 12 months as needed. A guideline rather than a primary study; the interval is a consensus operationalisation of trial evidence, and Indian guideline bodies differ on LDL targets. doi:10.1161/CIR.0000000000000625
Jonklaas J, Bianco AC, Bauer AJ, et al.; American Thyroid Association Task Force on Thyroid Hormone Replacement. Guidelines for the treatment of hypothyroidism. Thyroid. 2014;24(12):1670–1751 — TSH should be reassessed approximately 6 to 8 weeks after starting levothyroxine or changing the dose, reflecting the drug's roughly week-long half-life and the time to steady state. Guideline consensus; intervals differ in pregnancy, where reassessment is more frequent.
Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE. Defining the relationship between plasma glucose and HbA1c: analysis of glucose profiles and HbA1c in the Diabetes Control and Complications Trial. Diabetes Care. 2002;25(2):275–278 — establishes that HbA1c is a weighted rather than flat average: plasma glucose in the preceding 30 days contributes roughly 50% of the value, while glucose from 90 to 120 days earlier contributes only about 10%. Consistent with Tahara and Shima (1993), and with later modelling finding about half the movement towards a new HbA1c level is reached in around 30 days. Derived from a type 1 diabetes trial population, so exact weighting may differ elsewhere; HbA1c also remains unreliable where red cell turnover is altered, which includes iron-deficiency anaemia.
American Diabetes Association Professional Practice Committee. 6. Glycemic goals and hypoglycemia: Standards of Care in Diabetes—2025. Diabetes Care. 2025;48(Suppl 1):S128–S145 — Recommendation 6.2 advises assessing glycaemic status at least twice a year, and more frequently (for example every three months) for people not meeting glycaemic goals or with recent treatment changes. Graded E, meaning expert consensus rather than trial evidence; HbA1c is unreliable where red cell turnover is altered, which includes iron-deficiency anaemia, common in India. PMID 39651981
Kwee RM, Kwee TC. Whole-body MRI for preventive health screening: a systematic review of the literature. Journal of Magnetic Resonance Imaging. 2019;50(5):1489–1503 — systematic review and meta-analysis of twelve studies covering 5,373 asymptomatic subjects. Pooled prevalence of critical and indeterminate incidental findings together was 32.1% (95% CI 18.3–50.1), and separately 13.4% (9.0–19.5) and 13.9% (5.4–31.3). The pooled proportion of findings that were verified was 12.6% (3.2–38.8) — a follow-up rate, not a measure of how many proved serious. Six studies reported false positives, pooling to 16.0%, but with a 95% CI of 1.9–65.8%, so that figure carries almost no precision. Between-study heterogeneity was extreme and protocols differed, so every pooled percentage is indicative only. PMID 30932247
Ministry of Health and Family Welfare, Government of India. Operational Guidelines: Prevention, Screening and Control of Common Non-Communicable Diseases — Hypertension, Diabetes and Common Cancers (Oral, Breast, Cervical). National Health Mission / NP-NCD — population-based screening delivered through primary care, covering all men and women aged 30 years and above for hypertension, diabetes and oral cancer, and all women aged 30 years and above for cervical and breast cancer, with risk captured on a Community Based Assessment Checklist. First-line methods are visual inspection with acetic acid for cervix, clinical breast examination for breast and oral visual inspection, chosen for deliverability at sub-centre level rather than because they outperform cytology or mammography. Coverage and implementation vary substantially between states, so what is offered in practice may differ from what the framework specifies.
US Preventive Services Task Force; Curry SJ, Krist AH, Owens DK, et al. Screening for cardiovascular disease risk with electrocardiography: US Preventive Services Task Force recommendation statement. JAMA. 2018;319(22):2308–2314 — recommends against screening with resting or exercise ECG in asymptomatic adults at low risk of cardiovascular events (grade D), and concludes the evidence is insufficient to assess the balance of benefits and harms at intermediate or high risk (I statement). Applies only to asymptomatic adults; it says nothing about ECG where symptoms, examination findings or a planned treatment give a clinical reason. A US body, so it does not automatically transfer to Indian practice.
Nordestgaard BG, Langsted A, Mora S, et al.; European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine Joint Consensus Initiative. Fasting is not routinely required for determination of a lipid profile. European Heart Journal. 2016;37(25):1944–1958 — joint consensus concluding that non-fasting samples are appropriate for routine lipid assessment, with fasting reserved for situations such as non-fasting triglycerides above 440 mg/dL. The 2018 ACC/AHA cholesterol guideline reaches a compatible position. Consensus rather than a trial; laboratories and clinicians in India vary in whether they have adopted it, and most Indian packages bundle fasting glucose anyway, so fasting is usually requested regardless.
Ain KB, Pucino F, Shiver TM, Banks SM. Thyroid hormone levels affected by time of blood sampling in thyroxine-treated patients. Thyroid. 1993;3(2):81–85; and Sviridonova MA, et al. Clinical significance of TSH circadian variability. Endocrine Research. 2013 — TSH follows a diurnal rhythm, peaking around midnight and reaching its trough in the mid-afternoon, with individuals whose peak sits outside the reference range showing normal trough values. In levothyroxine-treated patients, free T4 rises for roughly three to four hours after the dose and falls to its lowest just before the next one, which is why samples are drawn pre-dose. Small studies in treated patients; the size of the diurnal swing varies between individuals and is rarely large enough on its own to change a clear diagnosis.
American Thyroid Association. Biotin and thyroid function tests — Clinical Thyroidology for the Public. 2018;11(12):3–4, and Ylli D, Soldin SJ, Stolze B, et al. Biotin interference in assays for thyroid hormones, thyrotropin and thyroglobulin. Thyroid. 2021;31(7):1160–1170 — many immunoassays use streptavidin-biotin chemistry, so circulating biotin can falsely raise T3 and T4 and falsely lower TSH, mimicking hyperthyroidism. The ATA advises stopping biotin at least two days before thyroid testing; the 2021 study, using 10,000 mcg daily, supports three to five days at high doses. Interference is platform-dependent and not every assay is affected. PMID 34042535
This article is for general information and is not a substitute for individual medical advice. Test results should be interpreted by a doctor in the context of your history, symptoms and examination. Treatment decisions, including whether to start or change any medication, should be made with a qualified clinician.
